crizotinib

{
  "id": "MLC-T-ONC-002140",
  "term": "crizotinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat certain types of ALK-positive inflammatory myofibroblastic tumors in adults and children aged 1 year and older, ALK-positive systemic anaplastic large cell lymphoma in young adults and children aged 1 year and older, and ALK-positive or ROS1-positive non-small cell lung cancer. It is also being studied in the treatment of other types of cancer. Crizotinib blocks certain proteins made by the ALK and ROS1 genes, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Xalkori.",
    "An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors."
  ],
  "synonyms": [
    "Xalkori",
    "MET Tyrosine Kinase Inhibitor PF-02341066"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/crizotinib/"
}